UNDERSTANDING HOW ONCOLYTIC VIRUSES TACKLE THE COLD TUMOR SPACE

January 26th, 2022. 17:00 - 18:05h CET

What you will learn:
• How re-engineered viruses can be used as cancer therapies, e.g. RP1+1
• Application of RP1+1 in different cancer types with a special interest in Squamous Cell Carcinoma of the Skin (SCCS)

Agenda
17:00 - 18:05h CET

Chairs: Dra. Ana Arance (Spain) & Dr. Ramón Alemany (Spain)

17:00 - 17:15 CET Building an optimal Oncolytic Viral Therapy
Speaker: Dr. Robert Coffin (USA)

17:15 - 17:30 CET Clinical development of RP1+1 to improve immunotherapy
Speaker: Dr. Kevin Harrington (UK)

17:30 - 17:45 CET Clinical Research Opportunities in SCCS
Speaker: Dr. Miguel Fernández de Sanmamed (Spain)

17:45 - 18:05 CET Live discussion

Free registration on the website www.internationalwebinargetica.com

Hosted by:

In collaboration with:

Speaker:

Dr. Ramón Alemany Bonastre
Scientist
ICO Institut Català d’Oncologia (ICO)
Barcelona, Spain

Dra. Ana Arance Fernández
GETICA President
Medical Oncology
Hospital Clinic de Barcelona
Barcelona, Spain

Dr. Robert Coffin
Chief Research & Development Officer
Replimune Inc.
Massachusetts, USA

Dr. Miguel Fernández de Sanmamed
Medical Oncology
Clinica Universidad de Navarra
Pamplona, Spain

Dr. Kevin Joseph Harrington
Professor in Biological Cancer Therapies
The Institute of Cancer Research
London, UK